← 홈

Antibody

14개 · ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-14 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 14개
AntibodyShanghai Shengdi Pharmaceutical…vedotin (RC48) in combinati…Phase 2

Adebrelimab (Adebrelimab)

Pancreatic Cancer · Advanced Solid Tumors

#AdvancedSolidTumors#Antibody#Phase2#인기#항체+5
임상시험 66상태 RECRUITING
AntibodyAstraZenecavedotin combined with pembr…Phase 3

Durvalumab (MEDI4736, MEDI4736 (Durvalumab))

Non-Small-Cell Lung Carcinoma NSCLC · Advanced Solid Tumors

#AdvancedSolidTumors#Antibody#Phase3#인기#항체+5
효능 ORR 36.3%임상시험 65상태 ACTIVE
AntibodystaleJeffrey ClarkePhase 1

AMG 479, Everolimus, Panitumumab (AMG 479, Everolimus, Panitumumab)

Advanced Solid Tumors, Non-small Cell Lung Cancer · Advanced Solid Tumors, Non-small Cell Lu

#AdvancedSolidTumorsNon-smallCell#Antibody#Phase1#항체#면역항체+4
임상시험 1상태 ACTIVE
AntibodystaleRochePhase 1

Bevacizumab, Everolimus and LBH589 (Bevacizumab, Everolimus and LBH589)

Advanced Solid Tumors · Advanced Solid Tumors

#AdvancedSolidTumors#Antibody#Phase1#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleSichuan Kelun-Biotech Biopharma…Phase 1

Drug: Tagitanlimab Drug: Capecitabine (Drug: Tagitanlimab Drug: Capecitabine)

Advanced Solid Tumors · Advanced Solid Tumors

#AdvancedSolidTumors#Antibody#Phase1#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleAstraZenecaPhase 1

durvalumab (Imfinzi, IPH5401 and Durvalumab)

Advanced Solid Tumors · Advanced Solid Tumors

#AdvancedSolidTumors#Antibody#Phase1#항체#면역항체+2
임상시험 1상태 DISCONTINUED
AntibodystaleMedImmune LLCPhase 2

durvalumab (Imfinzi, MEDI6469 Plus Durvalumab)

Advanced Solid Tumors; Aggressive B-cell Lymphomas · Advanced Solid Tumors

#AdvancedSolidTumors#Antibody#Phase2#항체#면역항체+3
효능 ORR 0%임상시험 1상태 DISCONTINUED
AntibodystaleMedImmune LLCPhase 2

MEDI6469 Plus Tremelimumab (MEDI6469 Plus Tremelimumab)

Advanced Solid Tumors; Aggressive B-cell Lymphomas · Advanced Solid Tumors

#AdvancedSolidTumors#Antibody#Phase2#항체#면역항체+3
효능 ORR 0%임상시험 1상태 DISCONTINUED
AntibodystaleMedImmune LLCPhase 2

MEDI6469 plus Rituximab (MEDI6469 plus Rituximab)

Advanced Solid Tumors; Aggressive B-cell Lymphomas · Advanced Solid Tumors

#AdvancedSolidTumors#Antibody#Phase2#항체#면역항체+3
효능 ORR 0%임상시험 1상태 DISCONTINUED
AntibodystaleHoffmann-La RochePhase 2

trastuzumab (Herceptin, ZN-A-1041 + PHESGO / Herceptin plus Perjeta injection for Phase 1b)

Advanced Solid Tumors; HER2-positive Breast Cancer · HER2

#HER2#Antibody#Phase2#항체#면역항체+4
임상시험 1상태 RECRUITING
AntibodystaleHoffmann-La RochePhase 2

trastuzumab (Herceptin, ZN-A-1041 + PHESGO / Herceptin plus Perjeta injection for Phase 1c)

Advanced Solid Tumors; HER2-positive Breast Cancer · HER2

#HER2#Antibody#Phase2#항체#면역항체+4
임상시험 1상태 RECRUITING
AntibodystaleEli LillyPhase 2

Cohort C2 Only (cetuximab, cetuximab (Cohort C2 Only))

Advanced Solid Tumors; Metastatic Solid Tumors · Advanced Solid Tumors

#AdvancedSolidTumors#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 RECRUITING
AntibodystaleEli LillyPhase 2

fulzerasib; cetuximab N01 (fulzerasib; cetuximab N01)

Colorectal Cancer; KRAS G12C Mutant Advanced Solid Tumors · Colorectal Cancer

#ColorectalCancer#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 RECRUITING
AntibodystaleAstraZenecaPhase 2

treme (tremelimumab, tremelimumab (treme))

Advanced Solid Tumors & Metastatic Squamous Cell Carcinoma of the Head and Neck · Advanced Solid Tumors & Metastatic Squam

#AdvancedSolidTumorsMetastaticSqu#Antibody#Phase2#항체#면역항체+2
효능 ORR 4.2%임상시험 1상태 ACTIVE